XXXIVth International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 18, 2021 | VIRTUAL CONFERENCE

Final Programme

www.ehmsg.org
Microbiota in Health and Disease, the official journal of the European Helicobacter and Microbiota Study Group – EHMSG, is focused on all issues related to the role of microbiota in maintaining health or promoting diseases, not only confined to the GI tract.

Its scope ranges from publishing papers on novelties in basic science, translational research, clinical trials and new therapeutic options, in order to supply international researchers with a valuable platform of discussion of challenges and opportunities in the field of microbiota.

You are kindly invited to submit your valuable paper completely FREE OF CHARGE

For submissions please visit the website: https://www.microbiotajournal.com
XXXIV\textsuperscript{th} International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 18, 2021 | VIRTUAL CONFERENCE
TABLE OF CONTENTS

Awardees of the Marshall and Warren Medal.......................................................... 4
Welcoming Address ................................................................................................. 5
Committees – Organisation ....................................................................................... 6
Workshops of the EHMSG ...................................................................................... 6
Save the Date for EHMSG 2022 ........................................................................... 7
Live Programme Saturday, September 18 ............................................................. 8
Poster Presentations ............................................................................................... 11
Satellite Symposium ............................................................................................... 21
Scientific Information ............................................................................................. 23
Acknowledgements ................................................................................................. 25
General Information ............................................................................................... 28

AWARDEES OF THE MARSHALL AND WARREN MEDAL

2021  Dulciene Queiroz, Belo Horizonte, Brazil
2020  Hazel Mitchell, Sydney, Australia
2019  Guillermo Perez-Perez, New York, NY, United States
2018  Kenneth McColl, Glasgow, United Kingdom
2017  Jean-Charles Delchier, France
2016  Ken Sugano, Shimotsuke, Japan
2015  Heidi-Ingrid Maaroos, Tartu, Estonia
2014  Manfred Kist, Freiburg, Germany
2013  Masahiro Asaka, Sapporo, Japan
2012  Richard Hunt, Hamilton, ON, Canada
2011  Samy Cadranel, Brussels, Belgium
2010  Reinhold W. Stockbrügger, Maastricht, The Netherlands
2009  Pelayo Correa, Nashville, TN, United States
2008  Timo Kosunen, Helsinki, Finland
2007  Mike Dixon, Leeds, United Kingdom
2006  Barry Marshall, Perth, Australia & Stanislav Konturek, Cracow, Poland

NEXT EHMSG WORKSHOP

September 8 - 10, 2022
Glasgow, United Kingdom
Welcoming address by the President of the European Helicobacter and Microbiota Study Group
Prof. Dr. Mirjana Rajilić-Stojanović

Dear Colleagues,
Dear Friends,

Please, receive my warmest welcome to the 34th Workshop of the European Helicobacter and Microbiota Study Group.

The EHSMG is dedicated to knowledge and experience exchange and in 2020, despite the pandemic, we continued to interact by organizing the first virtual EHSMG workshop. Although we are eager to meet again in a face-to-face meeting, keeping each other safe is our top priority and this year we will organize yet another online workshop.

For the second online EHMSG Workshop we promise an exciting agenda and world-class presenters that will share the latest findings in the dynamic field of gut microbiota and Helicobacter pylori research. While travel restrictions are hampering organisation of a traditional meeting, the online format of the workshop facilitates a platform in which top experts from different continents can join and discuss the latest findings in this exciting scientific area.

We hope that you will recognize the unique opportunity and that you will join us on September 18!

We are looking forward seeing you online!

Mirjana Rajilić-Stojanović
President of the European Helicobacter and Microbiota Study Group
Committees – Organisation

European Helicobacter & Microbiota Study Group EHMSG

President of the EHMSG
Mirjana Rajilić-Stojanović

Honorary Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Ernst Kuipers, The Netherlands
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Members and International Scientific Committee
Leif P. Andersen, Denmark
Lars Engstrand, Sweden
Antonio Gasbarrini, Italy
Javier P. Gisbert, Spain
Georgina Hold, Australia
Josbert Keller, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Peter Malferttheiner, Germany
Francis Mégraud, France
Colm A. O’Morain, Ireland
Mirjana Rajilić-Stojanović, Serbia
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece
Annemieke Smet, Belgium
Herbert Tilg, Austria

Corresponding Fellows
Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chung-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Emeritus Members
Anthony Axon, United Kingdom
Michel A.L. Deltenre, Belgium
Bram Flahou, Belgium
Giovanni Gasbarrini, Italy
Alexander M. Hirschl, Austria
Pierre Michetti, Switzerland
José M. Pajares Garcia, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal (†)
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Corresponding Fellows
Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chung-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Organizing Office

Core Agency
Scientific and Administrative Secretariat
Vienna Medical Academy
Catherine Tomek
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 18
Fax: +43 1 405 13 83 918
Email: workshop@ehmsg.org

Workshops of the EHMSG

Bordeaux (1988)
Ulm (1989)
Toledo (1990)
Bologna (1991)
Dublin (1992)
Brussels (1993)
Houston (1994)
Edinburgh (1995)
Copenhagen (1996)

Lisbon (1997)
Budapest (1998)
Helsinki (1999)
Rome (2000)
Strasbourg (2001)
Athens (2002)
Vienna (2004)
Copenhagen (2005)

Wroclaw (2006)
Istanbul (2007)
Riga (2008)
Porto (2009)
Rotterdam (2010)
Dublin (2011)
Ljubljana (2012)
Madrid (2013)
Rome (2014)

Nicosia (2015)
Magdeburg (2016)
Bordeaux (2017)
Kaunas (2018)
Innsbruck (2019)
Virtual Event (2020)
Virtual Event (2021)
Glasgow (2022)
Antwerp (2023)
XXXIVth International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 8 - 10, 2022 | Glasgow | United Kingdom

Abstract Submission Deadline: Sunday, May 8, 2022

www.ehmsg.org
## PROGRAMME SATURDAY, SEPTEMBER 18, 2021

**ALL TIMES ARE Central European Summer Time - CEST**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.15</td>
<td><strong>Session 1 - Welcome and introduction</strong></td>
</tr>
<tr>
<td>08.15 - 08.35</td>
<td><strong>Session 2 - Introductory lecture</strong></td>
</tr>
<tr>
<td>08.35 - 09.35</td>
<td><strong>Session 3 - Gastric carcinogenesis symposium</strong></td>
</tr>
<tr>
<td>08.35 - 08.55</td>
<td><strong>3.1 - Quiescent stem cells: differentiated cells reprogram to fuel repair, metaplasia and neoplasia in the adult stomach</strong></td>
</tr>
<tr>
<td>08.55 - 09.15</td>
<td><strong>3.2 - The hippo pathway in gastric carcinogenesis</strong></td>
</tr>
<tr>
<td>09.15 - 09.35</td>
<td><strong>3.3 - Extracellular vesicles from cancer-associated fibroblasts induce drug resistance</strong></td>
</tr>
<tr>
<td>09.45 - 10.05</td>
<td><strong>Session 4 - Gastric cancer (GC) symposium</strong></td>
</tr>
<tr>
<td>10.05 - 10.45</td>
<td><strong>4.1 - Autoimmune gastritis and risk of GC</strong></td>
</tr>
<tr>
<td>10.25 - 10.45</td>
<td><strong>4.2 - How to follow patients with gastric premalignant lesions?</strong></td>
</tr>
<tr>
<td>10.45 - 11.05</td>
<td><strong>4.3 - Mistakes in GC screening</strong></td>
</tr>
<tr>
<td>11.05 - 11.25</td>
<td><strong>4.4 - Elimination of GC related deaths in Japan</strong></td>
</tr>
<tr>
<td>13.00 - 13.20</td>
<td><strong>Session 6 - Awarding of the Marshall &amp; Warren Medal</strong></td>
</tr>
<tr>
<td>13.15 - 14.35</td>
<td><strong>Session 7 - H. pylori treatment symposium</strong></td>
</tr>
</tbody>
</table>

---

Please visit the virtual exhibition spaces of our sponsors and view the e-Posters.

---

**Session 1 - Welcome and introduction**

**Mirjana Rajilić-Stojanović & Tomica Milosavljevic**

**Session 2 - Introductory lecture**

**Chair: Francis Mégraud, Leif Andersen**

**2.1 - A tribute to Samy Cadranel: H. pylori infection in Pediatrics beginning in Brussels**

**Patrick Bontems (Brussels, Belgium)**

**Session 3 - Gastric carcinogenesis symposium**

**Chair: José Machado, Jae Gyu Kim**

**3.1 - Quiescent stem cells: differentiated cells reprogram to fuel repair, metaplasia and neoplasia in the adult stomach**

**Jason C Mills (St Louis, MI, USA)**

**3.2 - The hippo pathway in gastric carcinogenesis**

**Christine Varon (Bordeaux, France)**

**3.3 - Extracellular vesicles from cancer-associated fibroblasts induce drug resistance**

**Takatsugu Ishimoto (Kumamoto, Japan)**

---

**Session 4 - Gastric cancer (GC) symposium**

**Chair: Peter Malfertheiner, Theodore Rokkas**

**4.1 - Autoimmune gastritis and risk of GC**

**Christian Abnet (Rockville, MD, USA)**

**4.2 - How to follow patients with gastric premalignant lesions?**

**Tamara Matysiak Budnik (Nantes, France)**

**4.3 - Mistakes in GC screening**

**Marcis Leja (Riga, Latvia)**

**4.4 - Elimination of GC related deaths in Japan**

**Mototsugu Kato (Hakadate, Japan)**

---

**Session 5 - Satellite symposium**

*(see page 21 to view the detailed programme)*

---

**Session 6 - Awarding of the Marshall & Warren Medal**

**Chair: Francis Mégraud, Mirjana Rajilić-Stojanović**

**6.1 - Dulciene Queiroz (Belo Horizonte, Brazil)**

---

**Session 7 - H. pylori treatment symposium**

**Chair: Colm O’Morain, Tomica Milosavljevic**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.15 – 13.35</td>
<td>7.1 - Pathways of antimicrobial resistance through data sciences</td>
<td>Niyaz Ahmed (Hyderabad, India)</td>
</tr>
<tr>
<td>13.35 – 13.55</td>
<td>7.2 - The Korean registry on <em>H. pylori</em> eradication (Koreg): Transition in therapy</td>
<td>Joon Sung Kim (Seoul, Korea)</td>
</tr>
<tr>
<td>13.55 – 14.15</td>
<td>7.3 - What we have learned from the European <em>H. pylori</em> registry (HpEuReg)</td>
<td>Javier Gisbert (Madrid, Spain)</td>
</tr>
<tr>
<td>14.15 – 14.35</td>
<td>7.4 - Role of meta-analysis of <em>H. pylori</em> in the era of antimicrobial stewardship</td>
<td>David Graham (Houston, TX, USA)</td>
</tr>
<tr>
<td>14.35 – 14.45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>14.45 – 16.25</td>
<td>Session 8 - Microbiota symposium</td>
<td></td>
</tr>
<tr>
<td>14.45 – 15.05</td>
<td>8.1 - Gastric microbiota changes during gastric carcinogenesis as a diagnostic biomarker</td>
<td>Jae Yong Park (Seoul, Korea)</td>
</tr>
<tr>
<td>15.05 – 15.25</td>
<td>8.2 - Correlation of microbiota composition and COVID immunity</td>
<td>Mirjana Rajilic Stojanovic (Belgrade, Serbia)</td>
</tr>
<tr>
<td>15.25 – 15.45</td>
<td>8.3 - Million microbiome from humans project, MMHP</td>
<td>Lars Engstrand (Stockholm, Sweden)</td>
</tr>
<tr>
<td>15.45 – 16.05</td>
<td>8.4 - How gut microbiota alters the brain</td>
<td>Gerard Clarke (Cork, Ireland)</td>
</tr>
<tr>
<td>16.05 – 16.25</td>
<td>8.5 - Microbiota in NAFLD/MAFLD</td>
<td>Herbert Tilg (Innsbruck, Austria)</td>
</tr>
<tr>
<td>16.25 – 16.40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>16.40 – 18.00</td>
<td>Session 9 - Fecal Microbiota Transplantation (FMT) symposium</td>
<td>Georgina Hold, Herbert Tilg</td>
</tr>
<tr>
<td>16.40 – 17.00</td>
<td>9.1 - FMT in the COVID era</td>
<td>Josbert Keller (The Hague, The Netherlands)</td>
</tr>
<tr>
<td>17.00 – 17.20</td>
<td>9.2 - COVID risk during endoscopy and FMT</td>
<td>Gianluca Ianiro (Rome, Italy)</td>
</tr>
<tr>
<td>17.20 – 17.40</td>
<td>9.3 - FMT for IBD</td>
<td>Sam Costello (Adelaide, Australia)</td>
</tr>
<tr>
<td>17.40 – 18.00</td>
<td>9.4 - FMT to newborns</td>
<td>Katri Korpela (Helsinki, Finland)</td>
</tr>
</tbody>
</table>
18.00 – 18.30  Session 10 - Debate: Tools for modulating gut microbiota function, probiotics vs. prebiotics
Chair: Lars Engstrand, Josbert Keller

18.00 – 18.15  10.1 - Benefit of Prebiotics
Petia Petkova Datchary (Würzburg, Germany)

18.15 – 18.30  10.2 - Benefit of Probiotics
Muriel Derrien (Palaiseau, France)

18.30 – 19.00  Session 11 - Closing Session
Chair: Mirjana Rajilić-Stojanović, Georgina Hold

18.30 – 18.40  11.1 - Poster Awards
Mirjana Rajilić-Stojanović, Georgina Hold

18.40 – 19.00  11.2 - Presentation of the Workshop 2022 in Glasgow, United Kingdom
Georgina Hold (Sydney, Australia)
EP01 Electronic Poster Round 1: Diagnosis of Helicobacter infection

P01.01
Prevalence of clarithromycin resistant strains in Helicobacter pylori positive patients after COVID-19
Presenting Author: Valeriy Kryvy, Simferopol, Russian Federation

P01.02
New rapid H. pylori blood test based on FLID and Cag A antibodies detection
Presenting Author: Christian Schulz, Munich, Germany

P01.03
The frequency of false positive Helicobacter urease tests during the routine endoscopy is negligible low
Presenting Author: Alexander Link, Magdeburg, Germany

P01.04
Comparative evaluation of Helicobacter pylori susceptibility testing methods to optimize routine analysis.
Presenting Author: Véronique Miendje Deyi, Brussels, Belgium

P01.05
H. pylori diagnostic tests used in naïve patients: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ignasi Puig, Manresa, Spain

P01.06
The patient experience and clinical efficacy of a novel virtual 13C-UBT service at an Irish tertiary referral center during the Covid 19 pandemic.
Presenting Author: Sandeep Sihag, Dublin, Ireland

P01.07
Molecular diagnosis of Helicobacter pylori: validation of Allplex™ H. pylori and ClariR Assay
Presenting Author: Pierre Bogaerts, Yvoir, Belgium

P01.08
Comparison of histological examination and semi-quantitative detection of H. pylori infection: a pilot study.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation

P01.09
Helicobacter pylori infection-related metabolic and gastric mucosa pre-malignant histological parameters in Swiss bariatric patients
Presenting Author: Michael Doulberis, Aarau, Switzerland

P01.10
The prevalence of Helicobacter pylori infection among dyspeptic patients in Northwestern Romania: a decreasing epidemiological trend in the last 30 years
Presenting Author: Alexandra Corojan, Cluj-Napoca, Romania

P01.11
Molecular diagnosis and histopathology: is there a difference between the methods for detecting Helicobacter pylori in severe and non-severe esogastroduodenal lesions?
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P01.12
Two types of ammonium breath test for detection of H. pylori infection
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

P01.13
Accuracy of gastric biopsy-based methods for diagnosis of Helicobacter pylori infection in symptomatic Vietnamese children.
Presenting Author: Tu Nguyen Cam, Ho Chi Minh City, Viet Nam

EP02 Electronic Poster Round 2: Treatment of Helicobacter infection

P02.01
Efficacy of vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication: A prospective randomized study
Presenting Author: Sarita Ratana-Amornpin, Pathum Thani, Thailand
P02.02
A double-blind, placebo-controlled, multicenter study of the efficacy and safety of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis, associated with H. pylori
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

P02.03
Tackling Helicobacter pylori infection by a pre-clinical prophylactic vaccination strategy
Presenting Author: Verena Friedrich, Munich, Germany

P02.04
A multicenter study on the past use of metronidazole and the success rate of eradication of Helicobacter pylori
Presenting Author: Younghhee Choe, Seoul, Republic of Korea

P02.05
Treatments after failed therapy in H. pylori infected children in Europe: Results of the EuroPedHp Registry
Presenting Author: Thu Giang Le Thi, Munich, Germany

P02.06
First-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.07
Second-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.08
Quadruple hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance country: the importance of a close medical-patient relationship
Presenting Author: Catarina Correia, Coimbra, Portugal

P02.09
An observational real-life study evaluating the efficacy of 10 and 14-days Concomitant therapy supplemented with probiotics for H. pylori eradication in naïve patients in a high Clarithromycin and Metronidazole resistance area
Presenting Author: Kateryna Priadko, Napoli, Italy

P02.10
Primary antimicrobial resistance trend in Italian H. pylori naïve patients between 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.11
Vonoprazan-based dual therapy and high-dose PPI dual regimens for H. pylori eradication: A comparison of the available data
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.12
First-line empirical H. pylori eradication therapy in Europe: Results from 30,000 cases of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.13
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.14
Empirical second-line treatments in Europe: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.15
Experience with single capsule bismuth quadruple therapy in 5,000 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain
E-POSTER PRESENTATIONS

P02.16
Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ángeles Pérez-Aísa*, Marbella, Spain

P02.17
Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luis Bujanda, San Sebastián, Spain

P02.18
Experience with rifabutin-containing therapy in 426 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

P02.19
Non-bismuth quadruple concomitant treatment for H. pylori eradication: systematic review and meta-analysis
Presenting Author: Olga Nyssen, Madrid, Spain

P02.20
Eradication of Helicobacter pylori: meta-analysis-based or registry-based? A personal view.
Presenting Author: György Buzás, Budapest, Hungary

P02.21
Efficacy and safety of vonoprazan-based quadruple regimens for the eradication of Helicobacter pylori in Chinese patients with peptic ulcer: a pooled analysis of two phase III trials
Presenting Author: Xiaohua Hou, Wuhan, China

P02.22
Exploring the potential of bio-active components of Morinda citrifolia and its interaction with the Helicobacter pylori oncogenic protein CagA
Presenting Author: Oindrilla Mukherjee, Durgapur, India

P02.23
Gellan Gum hydrogels as a pH-responsive system to control the gastric delivery of highly effective antimicrobial microspheres against Helicobacter pylori
Presenting Author: Diana Fonseca, Porto, Portugal

P02.24
Comparative efficacy of eradication triple, sequential therapy and quadruple-therapy in patients after COVID-19
Presenting Author: Valeriy Kryvyi, Simferopol, Russian Federation

P02.25
Effective eradication regimen and duration according to the results of clarithromycin susceptibility of Helicobacter pylori.
Presenting Author: Byung-Wook Kim, Incheon, Republic of Korea

P02.26
Characteristics of empirical first- and second-line treatment prescribed between 2013-2020:Italian data from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

P02.27
Tuning up nanostructured lipid carriers for specific Helicobacter pylori eradication: effect of size, charge and protein corona
Presenting Author: Rute Chitas, Porto, Portugal

P02.28
PPI-amoxicillin dual therapy four times daily is superior to guidelines-recommended regimens in the Helicobacter pylori eradication therapy: a systematic review & meta-analysis
Presenting Author: Cailing Li, Beijing, China

P02.29
Comparison of the reading of Clarithromycin E-test on Helicobacter pylori by eye and with microscope
Presenting Author: Melodi Yusibova, København Ø, Denmark
**E-POSTER PRESENTATIONS**

**P02.30**  
Addition of *Saccharomyces boulardii* to standard triple therapy in eradication of *H. pylori*: adverse events and compliance  
Presenting Author: Olga Sjomina, Riga, Latvia

**P02.31**  
Production of biofilm as a feature positively correlated with clarithromycin resistance in *Helicobacter pylori*  
Presenting Author: Paweł Krzyżek, Wrocław, Poland

**P02.32**  
Assessment of First-Line Treatment in Greece: Data from the European Registry on *Helicobacter pylori* Management (Hp-EuReg)  
Presenting Author: Theodore Rokkas, Athens, Greece

**P02.33**  
Inhibitors of carbonic anhydrases as anti-*Helicobacter pylori* agents  
Presenting Author: Rossella Grande, Chieti, Italy

**P02.34**  
Efficacy of *H. pylori* eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β  
Presenting Author: Natalya Bakulina, Saint Petersburg, Russian Federation

**P02.35**  
Development of new synthetic surfactants with anti-Helicobacter effect  
Presenting Author: Elena Ermolenko, Saint-Petersburg, Russian Federation

**P02.36**  
Evaluation of first-line bismuth containing 7-day quintet therapy for *Helicobacter pylori* eradication  
Presenting Author: Yeji Choi, Seongnam-si, Republic of Korea

**P02.37**  
Adjuvant therapy with eupatilin improves the state of gastric mucosa in patients with *H.pylori*-associated chronic gastritis and diabetes mellitus type 2  
Presenting Author: Igor Skrypnyk, Poltava, Ukraine

**P02.38**  
Treatment and diagnosis of Helicobacter infection in Ukraine: successes and mistakes  
Presenting Author: Yana Nikiforova, Kharkiv, Ukraine

**P02.39**  
Metronidazole susceptibility testing for *Helicobacter pylori* isolates: comparing agar dilution method & Epsilometer test  
Presenting Author: Xueli Tian, Beijing, China

**P02.40**  
Comparison of the success rate of eradication of *Helicobacter pylori* between hemodialysis patients and non-hemodialysis patients  
Presenting Author: Seung Han Kim, Seoul, Republic of Korea

**P02.41**  
*Helicobacter pylori* & primary antibiotic resistance in the region of northeastern Romania  
Presenting Author: Elena Popovici, Bacau, Romania

**EP03 Electronic Poster Round 3: Gastric cancer**

**P03.01**  
Proteomic signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer  
Presenting Author: Xue Li, Beijing, China

**P03.02**  
Current smoking and *H. pylori* status is associated with precancerous lesions „missed” by serologic pepsinogen testing  
Presenting Author: Danute Razuka-Ebela, Riga, Latvia
P03.03
Estrogen and *Helicobacter pylori* CagA may induce stem cell and epithelial mesenchymal transition phenotype in diffuse type gastric adenocarcinomas
Presenting Author: Seungkyung Kang, Seoul, Republic of Korea

P03.04
Leukaemia Inhibitory Factor signalling for targeting Cancer Stem Cells in gastric adenocarcinoma
Presenting Author: Lornella Seeneevassen, Bordeaux, France

P03.05
Does microbial lactate play a role in gastric adenocarcinoma?
Presenting Author: Karla Vinasco-Pacheco, Sydney, Australia

P03.06
Reprogramming of gastric epithelial cells towards precancerogenic and proinvasive phenotype by secretome of *Helicobacter pylori*-activated fibroblasts
Presenting Author: Tomasz Brzozowski, Cracow, Poland

P03.07
Putative impact of CagA protein on DNA damage repair machinery during *Helicobacter pylori* infection
Presenting Author: Eleftherios Kontizas, Athens, Greece

P03.08
Ex-vivo profiling of volatile organic compounds released from gastric cancer and non-cancerous tissue
Presenting Author: Daria Slefarska, Kielce, Poland

P03.09
The role of the nonspecific immunity in the progression of gastric cancer associated with *Helicobacter pylori* infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.10
Role of claudin proteins for prediction of lymphatic or lymph node invasion among submucosal-invasive early gastric cancer
Presenting Author: Moon Kyung Joo, Seoul, Republic of Korea

P03.11
Reasons for refusing further endoscopic surveillance in patients with diagnosed precancerous gastric lesions
Presenting Author: Laura Rotberga, Riga, Latvia

P03.12
Periodontal disease, gingivitis, periodontitis, tooth loss & gastric adenocarcinoma: systematic review.
Presenting Author: Francisco Aguiar, São Paulo, Brazil

P03.13
Findings from the surveillance upper endoscopies in patients with gastric mucosal dysplasia at the baseline
Presenting Author: Laura Rotberga, Riga, Latvia

P03.14
Changes in lipid peroxidation and antioxidant protection in chronic atrophic gastritis and gastric cancer associated with *Helicobacter pylori* infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.15
Evaluation of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis and gastric cancer associated with *Helicobacter pylori* infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

P03.16
Polyphenols Intake and Gastric Cancer: A quick review that precedes a case-control study in the Amazon region of Brazil
Presenting Author: Marcela Fagundes, São Paulo, Brazil

EP04 Electronic Poster Round 4: *Helicobacter infection - pathogenesis and host response*
P04.01
*Helicobacter pylori* upregulate epithelial cortactin expression in a CagA- and JNK-dependent manner
Presenting Author: Steffen Backert, Erlangen, Germany

P04.02
*Helicobacter pylori* PqqE protease cleaves junctional adhesion molecule A to disrupt tight junction functions
Presenting Author: Ceu Figueiredo, Porto, Portugal

P04.03
Effect of *Helicobacter pylori* eradication on the recurrence of gastric cancer after endoscopic submucosal dissection
Presenting Author: Jong-Jae Park, Seoul, Republic of Korea

P04.04
Comprehensive integration of genome-wide association and gene expression studies reveals novel gene signatures for *Helicobacter*-induced gastric disease and potential therapeutic targets
Presenting Author: Mohamed Tarek Badr, Freiburg, Germany

P04.05
Inhibition of Polycomb Repressive Complex 2 expression and function by *Helicobacter pylori*.
Presenting Author: Rebecca FitzGerald, Dublin, Ireland

P04.06
*Helicobacter pylori* infection provides proangiogenic conditions in an experimental model of vascular endothelial cells
Presenting Author: Paulina Rusek-Wala, Lodz, Poland

P04.07
*Helicobacter pylori* infection, distribution of dupA virulence gene and associated clinical outcomes: the situation in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P04.08
Expression of apoptosis and proliferation proteins by the cells of inflammatory infiltrate of gastric lamina propria in patients with peptic ulcer disease
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P04.09
Revisited role of *Helicobacter pylori* cagPAI, CagA, VacA and GGT in apoptosis during infection of gastric epithelial cells
Presenting Author: Steffen Backert, Erlangen, Germany

P04.10
Local cytokine status in *Helicobacter pylori* infection
Presenting Author: Guzel Isaeva, Kazan, Russian Federation

P04.11
Analysis of the *Helicobacter pylori* vacA virulence gene in dyspeptic patients
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P04.12
Searching for cross-reacting antibodies produced during *Helicobacter pylori* infection in an experimental animal model
Presenting Author: Agata Tomaszewska, Lodz, Poland

P04.13
Downregulation of pro-regenerative activity of IL-33 in the milieu of *H. pylori* lipopolysaccharide
Presenting Author: Weronika Gonciarz, Lodz, Poland

P04.14
ADP-heptose is the determinant of *Helicobacter pylori* responsible for the dampening of HLA-II expression in macrophages
Presenting Author: Marina de Bernard, Padova, Italy

P04.15
Pro-inflammatory and anti-inflammatory cytokines and immunoglobulins in the development of chronic atrophic gastritis with *Helicobacter pylori* infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation
E-POSTER PRESENTATIONS

P04.16
TLR1-SNP-rs4833095-genotype is not associated with inflammation phenotype in *H. pylori*-negative patients
Presenting Author: Alexander Link, Magdeburg, Germany

P04.17
Analysis of indicators characterizing the systemic immune response in patients with *Helicobacter pylori*
Presenting Author: Elizaveta Ageeva, Simferopol, Russian Federation

P04.18
Association between the *Helicobacter pylori cagA* virulence gene and the severity of gastroduodenal lesions
Presenting Author: Mônica Barbosa, Goiânia, Brazil

EP05 Electronic Poster Round 5: Epidemiology

P05.01
Relationship of alcohol and tobacco consumption and the development of gastric adenocarcinoma
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.02
Detection of *Helicobacter suis* in pork meat products aimed to human consumption
Presenting Author: Miguel García-Ferrús, Valencia, Spain

P05.03
Evaluation of the chemoprotective role of pequi fruit (Caryocar brasiliense) in gastric cancer.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.04
Prevalence of *Helicobacter pylori* infection in asymptomatic children from Southeastern Brazil
Presenting Author: Ana Carlos, Botucatu, Brazil

P05.05
Dietary patterns and *Helicobacter pylori* infection in dyspeptic patients in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.06
Differences in management of *Helicobacter pylori* infection: an observational study
Presenting Author: Ruffin Ntounda, bruxelles, Belgium

P05.07
*Helicobacter pylori* is associated with uninvestigated dyspepsia in inhabitants of the Eastern Siberia administrative center
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P05.08
Relationship between food habits and the development of gastric adenocarcinoma.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

P05.09
Gastric cancer early mortality: a brazilian cohort study
Presenting Author: Tatiane Tiengo, São Paulo, Brazil

P05.10
Prevalence of *Helicobacter pylori* cagA, vacA, oipA and iceA genotypes in Russian patients with gastroduodenal diseases
Presenting Author: Alena Svarval, Saint Petersburg, Russian Federation

EP06 Electronic Poster Round 6: Microbiology and genomics of Helicobacter

P06.01
Phenotypic, Molecular, and Whole Genome Characterization of Antibiotic Resistance in Enterohpetic *Helicobacter* species
Presenting Author: Anthony Mannion, Cambridge, United States
P06.02
Detection & genotyping of \textit{H. pylori} in environmental samples
Presenting Author: Irene Hortelano Martin, Valencia, Spain

P06.03
Genetic diversity of \textit{Helicobacter pylori} strains isolated from single patients using Multilocus Sequence Typing (MLST)
Presenting Author: Parastoo Saniee, Tehran, Islamic Republic of Iran

P06.04
Potential role of single nucleotide polymorphism of gluP and cgt genes in \textit{H. pylori} biofilm formation
Presenting Author: Kartika Fauzia, Yufu, Japan

P06.05
Peptidoglycan as a marker for isolation of endosymbiotic \textit{Helicobacter pylori} and Staphylococcus from yeast
Presenting Author: Samira Heydari, Tehran, Islamic Republic of Iran

P06.06
Prophage elements in Greek \textit{Helicobacter pylori} clinical isolates
Presenting Author: Beatriz Martinez-Gonzalez, Athens, Greece

P06.07
\textit{Helicobacter pylori}’s type 4 secretion systems as a gastroduodenal diseases marker
Presenting Author: Bui Hoang Phuc, Yufu, Japan

P06.08
Comparative genomic analysis in Colombian \textit{Helicobacter pylori} isolates: a focus to virulence, antibiotic resistance, and population structure.
Presenting Author: Johanna Stepanian-Rozo, Bogotá, Colombia

P06.09
Genetic diversity of vacA variable i, d and c regions in \textit{Helicobacter pylori} isolates from individual hosts
Presenting Author: Parastoo Saniee, Tehran, Islamic Republic of Iran

EP07 Electronic Poster Round 7: Helicobacter and extragastroduodenal diseases

P07.01
Mucus-degrading microbiota and proinflammatory T-cell responses underlie \textit{Helicobacter pylori} induced colon carcinogenesis
Presenting Author: Anna Ralser, Munich, Germany

P07.02
Exploring the binding mechanisms of \textit{Helicobacter pylori} to colon epithelial cells and induced downstream signaling
Presenting Author: Anna Ralser, Munich, Germany

P07.03
Circulating ghrelin decrease following \textit{Helicobacter pylori} eradication
Presenting Author: Paula Mantero, Buenos Aires, Argentina

P07.04
Autoimmune disease did not result in a higher incidence of pernicious anemia among a cohort of 94 patients with active \textit{H. pylori} infection presenting to a rheumatology clinic
Presenting Author: Michael Lovy, Palm Springs, United States

P07.05
\textit{Helicobacter pylori} infection, monoclonal gammopathy of uncertain significance, and autoimmune disease in a cohort of 150 patients with pernicious anemia
Presenting Author: Michael Lovy, Palm Springs, United States

P07.06
Screening and diagnosis of \textit{Helicobacter pylori} infection and autoimmune gastritis in patients with inflammatory bowel diseases
Presenting Author: Mila Kovacheva-Slavova, Sofia, Bulgaria
E-POSTER PRESENTATIONS

P07.07
Prevalence & impact of Helicobacter pylori in patients with cirrhosis
Presenting Author: Nouha Trad, Ariana, Tunisia

P07.08
The frequency of Helicobacter pylori and the structure of the gastric mucosa in elderly patients with esophagitis
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

P07.09
Comorbidity profile according to Helicobacter pylori infection status
Presenting Author: Mônica Barbosa, Goiânia, Brazil

EP08 Electronic Poster Round 8: Paediatric conditions

P08.01
Faecal microbiota in infants and toddlers with allergy
Presenting Author: Erika Luse, Riga, Latvia

P08.02
Cytokine profile in schoolchildren with Helicobacter pylori with familial burden of stomach cancer
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.03
Cytokine levels in Helicobacter pylori associated gastritis in children with familial burden of peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.04
The course of Helicobacter pylori associated gastritis in schoolchildren of Buryatia
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.05
CK20 in gastric mucosa in children with Helicobacter pylori-associated gastritis with superimposed GERD
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.06
Expression of CK20 in the stomach in children with Helicobacter pylori and familial predisposition to peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

P08.07
CK7 in schoolchildren with Helicobacter pylori-associated gastritis
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

EP09 Electronic Poster Round 9: Gut microbiota and non-intestinal diseases

P09.01
Effects of indigenous fecal bacteria consortium treatment in patients with metabolic syndrome
Presenting Author: Konstantin Ermolenko, Saint-Petersburg, Russian Federation

EP10 Electronic Poster Round 10: Microbiota and intestinal diseases

P10.01
Double blind RCT study on the efficacy of L. reuteri 4659 in reducing inflammatory markers in patients affected by acute uncomplicated diverticulitis
Presenting Author: Veronica Ojetti, Rome, Italy

P10.02
Effects of cytokines in chronic gastroduodenitis associated with Helicobacter pylori, fungi and protozoa invasion
Presenting Author: Elena Agafonova, Kazan, Russian Federation
P10.03
Rifaximin for small intestinal bacterial overgrowth: a retrospective study
Presenting Author: Carolina Mosoni, Rome, Italy

P10.04
Gut microbiota modification in patients with inflammatory bowel diseases who do not received and received biological therapy
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

EP11 Electronic Poster Round 11: Microbiota and cancer

P11.01
Presence of colibactin-producing E.coli in biliary juice and development of cholangiocarcinoma
Presenting Author: Parastoo Saniee, Tehran, Islamic Republic of Iran

P11.02
Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis
Presenting Author: Jae Gyu Kim, Seoul, Republic of Korea

EP12 Electronic Poster Round 12: Gut microbiota manipulation

P12.01
Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during the Helicobacter pylori eradication therapy
Presenting Author: Sara Cifuentes, Quito, Ecuador

P12.02
Fecal microbiome transplantation for recurrent CDI treatment: efficacy, short and long-term follow-up results from consecutive case series.
Presenting Author: Tadas Urbonas, Kaunas, Lithuania

EP13 Electronic Poster Round 13: Microbiota detection and analyses

P13.01
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol associated liver disease
Presenting Author: Dionisi Tommaso, Rome, Italy

P13.02
Gut bacteria functionality profiles and diversity index detected by the GA-map® Dysbiosis Test Lx
Presenting Author: Kristin Gravdal, Oslo, Norway

P13.03
Effects of green tea and post-fermented green tea extract on obese adults: a randomized double-blind, placebo-controlled trial focused on change of gut microbiota
Presenting Author: Munjin Ju, Seongnam, Gyeonggi, Republic of Korea

P13.04
A portable H2-breath tracker: laboratory assessment.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation
Saturday, September 18, 2021

11.05 - 12.05  **Session 5 - Chinese Experience**  
Chair: Prof. Lya Zhou, Prof. Yiqi Du, Prof. Javier Gisbert

11.05 - 11.35  **5.1 - The role of *H. pylori* detection in the gastric cancer screening**  
Speaker: Prof. Yiqi Du

11.35 - 12.05  **5.2 - A nationwide cross-sectional survey on the diagnosis and treatment of *Helicobacter pylori* infection by Chinese doctors**  
Speakers: Prof. Liya Zhou & Prof. Zhiqiang Song
CHANGING THE LANDSCAPE IN GI

Going beyond to advance treatments for patients with acid-related disorders

We believe we can change the status quo of treatment for acid-related disorders.

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid-related gastrointestinal (GI) disorders.

Learn more at phathompharma.com
LIVE SESSIONS

Session Structure for Live Presentations
All sessions include pre-recordings as well as a live component. We want to make sure to retain as much human interaction as possible.
Prior to the session, all lectures are recorded and uploaded to our system. They need to be of an exact length (as indicated in your information mailing) to ensure smooth development of the session.
At the scheduled timeslot of the session, the chairperson of the session will open the session and introduce the speakers.
Then the recording of the first lecture will be played. At all times there is a live-chat available, where all participants can contribute to the session or ask questions which will be monitored by the moderator.
After each lecture, there is some time reserved for a discussion with the chairperson. Lecturers and chairpersons therefore need to be online at the scheduled timeslot. They will discuss questions from the audience or further details of the session. This is the same procedure for all lectures.

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest (current and in the past 3 years) on the first slide.
A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

Speaking Time
The chairpersons of live sessions will be strict in allowing no more than the time allotted to discussions following the pre-recorded presentations.
Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.

e-POSTER PRESENTATIONS
E-Poster presentations can be viewed by participants “on-demand”, which means that individual presentations do not have dedicated times at which they can be viewed – they can be viewed at any time. Authors of e-Poster presentations can be contacted via a messaging system on the conference platform as of September 18, 2021.

AVAILABILITY OF PRESENTATIONS DURING AND AFTER THE CONFERENCE
All on-demand and e-poster presentations will be available (for registered participants only) on the virtual platform on the day of the conference and remain there for review until one month after the conference.
All live presentations will be moved to the on-demand section after September 18, 2021 and remain available there for review (for registered participants only) until one month after the conference.
GastroPanel® quick test

Revolutionary quick test innovation of the unique GastroPanel® is now available!

GastroPanel® quick test is the further development of the unique Biohit GastroPanel examination. GastroPanel quick test allows fast diagnosis of and screening for Helicobacter pylori, atrophic gastritis with related risks as well as high acid output of stomach in symptomatic and asymptomatic patients. The GastroPanel quick test speeds up the referral to further examinations. GastroPanel® findings - i) Helicobacter pylori infection, ii) atrophic gastritis or iii) high acid output are indications for gastroscopy and biopsy examination.

GastroPanel quick test saves costs and unnecessary clinical appointments.

It significantly improves the patient safety, as it speeds up the referral to further examinations, treatment and follow-up.

- **Sample:** EDTA-plasma
- **Test principle:** immunological lateral-flow test for detecting GastroPanel biomarkers
- **Kit components:** test cassette, sample dilution tubes with buffer, instructions for use.

www.biohithealthcare.com
Laippatie 1, 00880 Helsinki, Finland • info@biohit.fi • Tel. +358 9 773 861
EHMSG gratefully acknowledges the support of the following sponsors

Platinum Sponsor

RICHEN EUROPE S.R.L.
COMPANY OF RICHEN GROUP

Educational Grant

Takeda

Silver Sponsors

BIOCODEX
healthcare with passion and conviction

BIOHIT HealthCare
Innovating for Health
ACKNOWLEDGEMENTS

EHMSG gratefully acknowledges the support of the following sponsors

Silver Sponsors

INFAI

MAYOLY LABORATORIES

Phathom PHARMACEUTICALS

Other Sponsors

meridian BIOSCIENCE

sercon
At Mayoly Spindler, we are committed to your health. To become a leading reference in gastroenterology and dermo-cosmetics, we work daily to develop, produce and bring you better health solutions. French, independent and International Mayoly Spindler stands for its core values of responsibility, respect and pragmatism.

COMMITTED TO YOU HEALTH EVERY DAY.
www.mayoly-spindler.com
GENERAL INFORMATION

In alphabetical order.

Breaks and Lunch Break
During the session breaks we invite you to visit our sponsors virtual exhibition spaces as well as the e-Poster presentations.

Cancellations and Refunds
Registration fees may be refunded if written cancellation has been received as follows:
- until July 12, 2021: 50% refund
- from July 13, 2021: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering to EHMSG 2021, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Refunds will be made after September 18, 2021

Certificate of Attendance
Confirmations of attendance will be issued to registered participants after completion of an online survey.

CME Credits
The 34th Workshop of the European Helicobacter and Microbiota Study Group has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s).

Functionality of the virtual platform
The conference organiser’s subcontractors provide a high level of availability of their network, cannot however give any guarantee that their network will operate without any interruptions or malfunctions.
No assurances or guarantees can be given about the availability, quality, operation or support services for data traffic, on the networks, or lines of the participant’s Internet provider.
The conference organiser is not liable if the provision of the services is interrupted, partially restricted, or impossible as a result of force majeure. Force majeure is for example considered natural phenomena of significant intensity (avalanches, floods, etc.), conflicts, terrorism, strikes, unexpected official restrictions, power cuts, computer viruses, worms, Trojan horses etc.

Language
The official language of the workshop is English (no simultaneous translation).

Liability
In registering for the EHMSG 2021 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Virtual Conference and Virtual Exhibition on September 18, 2021
08.00 – 19.00 hrs CEST
All Live Talks and e-Poster presentations will be available in the On-Demand Section after the conference as of September 19, 2021 until October 19, 2021.
WHEN PRESCRIBING ANY ANTIBIOTIC, PAIR IT WITH ENTEROL®
Payment modalities

Payment of Registration Fees, may be made in EURO by:
- Credit Card: Mastercard, Visa and Diners Club.
- Bank Transfer to the conference account until September 10, 2021.
Payments need to be made without charges for the beneficiary. Clearly state the registration number, invoice number and participant’s name when processing the transaction.
When registering for the conference, you will have to agree to the General Terms and Conditions

Registration Details

Registration Fees (one fee applies for all participants)

| Regular Participants | EUR 100.– |

Payment of Registration fees may be made either by Credit Card (Diners Club, Mastercard and Visa) at any time, or by bank transfer until September 10, 2021

What is covered by the registration fee?
- Access through the virtual platform to all scientific sessions
- Access through the virtual platform to all recorded sessions until October 18, 2021
- Access through the virtual platform to all company exhibition spaces

Speakers & e-Poster Authors

ORAL PRESENTATIONS

Preparation of your presentation
- Please note, that the deadline for upload of your presentation is September 5, 2021. You are kindly requested to respect this deadline since our technical team will have to review all presentations to check if they are all working flawlessly and this requires some time. We cannot guarantee a technical check for presentations received after this deadline and cannot take any liability for any technical issues related to a late upload.
- How to pre-record your presentation
To pre-record your presentation, we suggest to use the built-in feature called “Record Presentation” in Powerpoint to be found inside the Slideshow-Ribbon.
Please see the detailed guidelines for recording in either MS PowerPoint 2010, 2013, 2016 or PowerPoint 365.

Technical guidelines for uploading your presentation
- Your talk needs to be uploaded to the platform as a mp4 file. Speakers will receive the upload link via email.
- The name of your presentation file should include:
  - Presentation number
  - Presenter’s name (First Name Last Name)
  (for example P01.01_John Smith).
- The official conference language is English. Therefore, all presentations are to be held in English.
- Your presentation must include an audio file within your Powerpoint presentation. Please see attached for instructions on how to add audio to your presentation.
  - Audio and movies: Make sure that all of your audios and videos are embedded into the powerpoint file.
- Format: presentation files will be accepted as Rehearsed Video Export of your Powerpoint presentation. Macintosh presentations (i.e. Keynote) or pdf cannot be accommodated.
- The size of your presentation must not exceed 500 MB.
- Videos and animations are supported but will be automatically started with the slide.
- Fonts: Do not use special fonts which are not part of the standard PowerPoint package, as this will cause problems while uploading your file or choose to embed them when saving.
- File name: The name of the presentation file should include presentation number and the presenter’s name.
In addition, it should have a maximum of 40 characters. To avoid any compatibility problems, please do not use special characters (e.g. «, Ö, Ø, ñ, ε, ®, ý, }, {, etc.) to name your presentation.
- Do not use any passwords, encryption or protection for your presentation.
- Please note that macros must not be used and flash-animations are not supported.
- Aspect ratio of your presentation should be 16:9 landscape (mandatory).
- If desired, you can add your picture/video to the presentation on the best possible position depending on your slides.
Live Talks
- Live means that the session will be streamed live via the virtual platform at the date and time indicated above. The “live” element only refers to the live Q&A / discussion. The presentation itself needs to be pre-record by the speaker and uploaded to the virtual platform ahead of the meeting. Detailed technical instructions on how to prepare and upload your pre-recorded presentation are attached to this mail.
- To make the virtual meeting more interactive and exciting for participants, you are kindly asked to be present during the live session in which your talk is scheduled and to answer questions from the audience.
- Questions will be monitored by the session moderators in the session chat and will be directed to you after your pre-recorded presentation has been played.
- Further information on how to access the speakers/moderators section of the virtual conference platform will follow by beginning of September.

Pictures
Note that your presentation will be converted into a file format that does not allow downloads of your talk. But just like in a real conference, it is possible for the registered participants to make photographs or screen shots of your presentation. If you do not wish any scientific content of your presentation to be photographed, please indicate this on the according slide(s) in a clearly visible way.

Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest (current and in the past 3 years) on the first slide. An example slide can be found here. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts. If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

E-POSTER PRESENTATIONS
Preparing your e-Poster Presentation
File name: The name of your file presentation file should include:
- Final publication number (see notification mail)
- Presenter’s name
To avoid any compatibility problems, please do not use special characters (e.g. «, Ö, Ø, ñ, ε, ®, ý}, { etc.) to name your presentation.

Change of Presenter/Withdrawal
If you are not able to present your e-Poster, you are kindly requested to contact the organising office as soon as possible to withdraw your abstract from the system.
In case of a change of presenter, please nominate a co-author who is not presenter of another abstract already and send us the full name and E-mail address of the co-author who will present the paper.

Slide Design
1. Text: Your guiding principle should be “As much as necessary, as little as possible”. The text should be concise and to the point, key facts may be highlighted.
2. Colours: Colours should be used sparingly. Choose colour combinations that make your text easy to read (preferably dark background – light fonts; avoid red and green).
3. Layout: Keep data on the slides simple. Ensure a logical order of the content. A clear and well-structured arrangement is the most attractive and the easiest to read.
4. Images: It is recommended that you collect your illustration material well in advance. Do not select too many images and concentrate on those which support your key points and conclusions optimally.
5. The official conference language is English. Therefore, all presentations are to be prepared in English.
In case of any technical problems during the upload, please contact us at support@steinerlive.com

Uploading your Poster
Posters must be uploaded to the EHMSG 2021 Virtual Meeting presentation management system. Further instructions (f.e. your personal upload link will follow by email.
Upload will be possible as of July 15, 2021.
Deadline for upload of your e-Poster is September 5, 2021 at 23.59hrs CEST.

Twitter
The European Helicobacter and Microbiota Study Group is present on Twitter @ehmsg
We invite you to follow us on Twitter, engage and discuss with your colleagues.
New Instruments Generations in Breath Test Analysis

TIME FOR CHANGE

IR-FORCE 200 Android

IR-FORCE 200 Fancy

IR-FORCE 300 Plus
Helicobacter Test INFAI®

One of the most used $^{13}$C-urea breath tests for the diagnosis of Hp-infections worldwide

- New line of INFAI packaging and serialization according the EU's Falsified Medicines Directive
- More than 7.0 million Helicobacter Test INFAI performed worldwide
- Registered in more than 40 countries worldwide
- First approved Hp test for children from the ages of 3 to 11
- Modified Hp test for patients taking PPIs (REFEX)
- Modified Hp test for patients with atrophic gastritis
- Cost-effective CliniPac Basic for hospital and GPs use